Evidence map›Paper›PMID 40216709›Full record

ArticleThe AAPS journal2025

A Tool to Eliminate IgM Immunoassay Interference.

Alexander Pöhler, Uwe Wessels, Roland F Staack, Maria Nordgren, Rolf Lood, Kay-Gunnar Stubenrauch

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexander PöhlerRoche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Bioanalysis & Biomarkers, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany. alexander.poehler@roche.com.
Uwe WesselsRoche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Bioanalysis & Biomarkers, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany.
Roland F StaackRoche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Bioanalysis & Biomarkers, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany.
Maria NordgrenGenovis AB, Karl Johans väg 104, SE-244 21, Kävlinge, Sweden.
Rolf LoodGenovis AB, Karl Johans väg 104, SE-244 21, Kävlinge, Sweden.
Kay-Gunnar StubenrauchRoche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Bioanalysis & Biomarkers, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IgM-selective proteolytic cleavage can become a groundbreaking tool for immunoassay-based bioanalysis. We tested the utility of a newly introduced IgM-selective protease in three different bioanalytical applications and showed that protease treatment can eliminate rheumatoid factor interference and simplify IgM isotyping. Surprisingly, we discovered that a gene therapy-induced immune response was underestimated in an anti-capsid IgG assay when treatment-emergent IgM were present in the matrix. Selective IgM digestion eliminated this interference.

Indexed as

Immunoglobulin MPeptide HydrolasesHumansImmunoassayImmunoglobulin GRheumatoid FactorImmunoglobulin GImmunoglobulin MPeptide HydrolasesRheumatoid FactorAnti-AAV assayIgM interferenceIgM proteaseImmunoassayRheumatoid factor interference

Identifiers

PMID40216709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.